Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    "Streptococcal Meningitis"
Previous Study | Return to List | Next Study

Treatment With Tamoxifen in Cryptococcal Meningitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03112031
Recruitment Status : Active, not recruiting
First Posted : April 13, 2017
Last Update Posted : February 12, 2019
Sponsor:
Collaborators:
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Cho Ray Hospital, Ho Chi Minh City, Vietnam
University of Liverpool
University of Rochester
Liverpool School of Tropical Medicine
Information provided by (Responsible Party):
Oxford University Clinical Research Unit, Vietnam

Brief Summary:
The purpose of this study is to develop initial efficacy, feasibility, and safety data regarding the use of Tamoxifen in combination with amphotericin B and fluconazole in the treatment of cryptococcal meningitis. The results of the study will inform the design and feasibility of a larger study powered to a survival endpoint. The study hypothesis is that adding tamoxifen to standard antifungal therapy increases the rate of clearance of yeast from cerebrospinal fluid. Increased rates of clearance of yeast from cerebrospinal fluid have previously been associated with improved clinical outcomes, including survival and disability.

Condition or disease Intervention/treatment Phase
Meningitis Streptococcal Hiv Meningitis Meningoencephalitis Drug: Tamoxifen Drug: Amphotericin B Drug: Fluconazole Phase 2

Detailed Description:

A randomized, open-label trial with 2 parallel arms: standard antifungal therapy versus tamoxifen augmented antifungal therapy during the first 2 weeks (induction phase) of treatment. The study will recruit in two sites in Ho Chi Minh City: the Hospital for Tropical Diseases (HTD), and Cho Ray Hospital (CRH). 25 patients will be enrolled into the two study arms (intervention versus control). All anti-fungal administration will be directly observed by ward staff.

Intervention arm: Induction phase treatment (days 1-14): Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. In addition patients will receive amphotericin 1mg/kg once daily iv and fluconazole 800mg once daily orally. The tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.

Control arm: Induction phase treatment (days 1-14): Patients will receive amphotericin 1mg/kg/day combined with fluconazole 800mg once daily for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously.

The primary efficacy endpoint will be the rate of clearance of yeast cells from cerebrospinal fluid (CSF) over the first 2 weeks following randomisation. Patients will be followed for 10 weeks, which is conventional in clinical trials in cryptococcal meningitis. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end. At this point, HIV infected patients will be switched to long term secondary prophylaxis with fluconazole 200mg/day as per standard practice. For HIV uninfected patients, the decision to continue antifungal treatment, and at which dose, will be made on a case by case basis by the attending physician in consultation with the patient.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis
Actual Study Start Date : October 10, 2017
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: Tamoxifen augmented antifungal therapy
Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
Drug: Tamoxifen
Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
Other Name: Nolvadex - D

Drug: Amphotericin B
Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
Other Name: Amphotret

Drug: Fluconazole
Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
Other Name: Zolmed 200

Active Comparator: Standard antifungal therapy
Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
Drug: Amphotericin B
Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
Other Name: Amphotret

Drug: Fluconazole
Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
Other Name: Zolmed 200




Primary Outcome Measures :
  1. Early Fungicidal Activity (EFA), i.e. the rate of clearance of yeast from cerebrospinal fluid [ Time Frame: over the first 2 weeks following randomisation ]
    In the trial, lumbar punctures are scheduled on days 1, 3, 7, 14, and additionally as clinically indicated. Whenever a lumbar puncture is performed, the study team will determine the amount of viable yeast in CSF through culture. Based on the patients' longitudinal quantitative yeast count measurements, EFA will be determined as previously described e.g. see N Engl J Med 2016; 374:542-54


Secondary Outcome Measures :
  1. Survival until 10 weeks after randomization [ Time Frame: 10 weeks after randomisation ]
    International treatment guidelines recommend 10 weeks of high dose antifungal therapy for cryptococcal meningitis - an initial phase of amphotericin based induction therapy for 2 weeks followed by 8 weeks of moderate to high dose fluconazole. The rate of survival until this 10 week period of therapy is completed is a frequent endpoint in trials of treatment for cryptococcal meningitis.

  2. Disability at 10 weeks [ Time Frame: at 10 weeks ]
    Disability is an expected consequence of cryptococcal meningitis, including blindness, deafness and other focal neurological deficits. Neurological disability will be assessed using the modified Rankin score and the Two Simple Questions, and the results of each test combined and classified as good, intermediate, severe disability, or death, as we have previously published.

  3. Adverse events [ Time Frame: During hospital stay, an average of 10 weeks ]
    The proportion of patients with any grade 3 or 4 adverse event, serious adverse event, or unexpected serious adverse event will be compared between treatment groups.

  4. Rate of IRIS until 10 weeks (in HIV infected patients only) [ Time Frame: until 10 weeks ]
    The investigators will model the rate of IRIS over time with a cause-specific hazards model taking into account the competing risk of prior death.

  5. Rate of Cryptococcal meningitis relapse [ Time Frame: until 10 weeks ]
    A pragmatic definition of relapse will be used. This is defined as either intensification of antifungal therapy above that according to the study antifungal schedule, or readmission for treatment of cryptococcal disease.

  6. QT prolongation [ Time Frame: During hospital stay, an average of 10 weeks ]
    Prolongation of the QT interval is a potential side-effect of both Tamoxifen and fluconazole, although it is not clear that either drug increases the risk of Torsade de Pointes, a potentially life-threatening arrhythmia. The QT interval will be estimated manually from 3 chest and 3 limb leads from a high resolution (50mm/sec) 12-lead ECG. The median value will be determined and used to calculate the corrected QT interval (QTc) using using Framingham's formula

  7. Visual deficit at 10 weeks [ Time Frame: at 10 weeks ]
    Visual deficit occurs in 5-40% of patients with cryptococcal meningitis depending upon underlying immune status. The pathogenesis is unclear. The study team will compare the incidence of blindness and other visual deficit between treatment groups. Visual deficit will be assessed using a simple 6 point scale.

  8. Time to new neurological event or death until 10 weeks [ Time Frame: until 10 weeks ]
    A neurological event is defined as a fall in Glasgow coma score by ≥2 points for ≥2 days from the highest previously recorded Glasgow coma score (including baseline) or the occurrence of any of the following adverse events: cerebellar symptoms, coma, hemiplegia, paraplegia, seizures, cerebral herniation, new onset blindness or deafness, or cranial nerve palsy.

  9. Longitudinal measurements of intracranial pressure during the first 2 weeks [ Time Frame: during the first 2 weeks ]
    Intracranial pressure (ICP) will be measured at study entry, day 3, 7, and 14, and at other times as clinically indicated. The decline in raised intracranial pressure over the first 2 weeks will be modelled and compared between treatment arms.

  10. CD4 count at 10 weeks [ Time Frame: at 10 weeks ]
    CD4 count measurement is indicated in HIV infected patients, and CD4 lymphopenia has been described in HIV uninfected patients with cryptococcal meningitis. Moreover, Tamoxifen may reduce CD4 cell apoptosis which may be beneficial.

  11. Blood and CSF concentrations of amphotericin, Tamoxifen and fluconazole [ Time Frame: During hospital stay, an average of 10 weeks ]
    All patients will undergo pharmacokinetic sampling to enable the description of the concentrations of Tamoxifen and fluconazole in plasma and CSF, and of amphotericin in blood, and relate these to the rate of clearance of yeast from CSF.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Cryptococcal meningitis (CM) defined as a syndrome consistent with CM and one or more of:

    • positive CSF India ink (budding encapsulated yeasts),
    • C. neoformans cultured from CSF or blood,
    • positive cryptococcal antigen Lateral Flow Antigen Test (LFA) in CSF
  • Informed consent to participate given by patient or acceptable representative
  • Known HIV infection status, or patient agrees to HIV testing on this admission

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • History of thromboembolic disease such as pulmonary embolism or deep venous thrombosis
  • On anti-coagulant medication
  • On medication known to prolong the QT interval other than fluconazole, such as fluoroquinolones or antidepressants.
  • Known cardiac conduction defect including long QT syndromes
  • QTc at baseline > 500ms
  • Currently receiving treatment for cryptococcal meningitis and having received > 4 days of anti-cryptococcal meningitis therapy
  • Known allergy to Tamoxifen
  • Currently or history of receiving treatment with Tamoxifen for breast cancer or other indication
  • Current or history of uterine cancer including endometrial cancer and uterine sarcoma
  • Renal failure (defined as creatinine >3*ULN (upper limit of normal), despite adequate hydration)
  • Failure to consent - the patient, or if they are incapacitated, their responsible relative, declines to enter the study
  • Allergy to amphotericin B or fluconazole

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03112031


Locations
Layout table for location information
Vietnam
Cho Ray Hospital
Ho Chi Minh City, Vietnam
Hospital for Tropical Diseases
Ho Chi Minh City, Vietnam
Oxford University Clinical Research Unit
Ho Chi Minh City, Vietnam
Sponsors and Collaborators
Oxford University Clinical Research Unit, Vietnam
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
Cho Ray Hospital, Ho Chi Minh City, Vietnam
University of Liverpool
University of Rochester
Liverpool School of Tropical Medicine
Investigators
Layout table for investigator information
Principal Investigator: Jeremy Day, MD Oxford University Clinical Research Unit

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Oxford University Clinical Research Unit, Vietnam
ClinicalTrials.gov Identifier: NCT03112031     History of Changes
Other Study ID Numbers: 28CN
First Posted: April 13, 2017    Key Record Dates
Last Update Posted: February 12, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Oxford University Clinical Research Unit, Vietnam:
Tamoxifen
Cryptococcal meningitis
Cryptococcus neoformans
Human immunodeficiency virus

Additional relevant MeSH terms:
Layout table for MeSH terms
Meningitis
Meningitis, Cryptococcal
Meningoencephalitis
Central Nervous System Diseases
Nervous System Diseases
Meningitis, Fungal
Central Nervous System Fungal Infections
Mycoses
Cryptococcosis
Central Nervous System Infections
Encephalitis
Brain Diseases
Central Nervous System Viral Diseases
Tamoxifen
Fluconazole
Miconazole
Amphotericin B
Liposomal amphotericin B
Antifungal Agents
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors